A randomized trial to assess the efficacy and safety of ABT-126, a selective α7 nicotinic acetylcholine receptor agonist, in the treatment of cognitive impairment in schizophrenia

American Journal of Psychiatry

Volumn 173, Issue 8, 2016, Pages 827-835

  Haig, George M ^a   Bain, Earle E ^a   Robieson, Weining Z ^a   Baker, Jeffrey D ^a   Othman, Ahmed A ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(5 PHENYL 1,3,4 THIADIAZOL 2 YL)OXY] 1 AZONIATRICYCLO[3.3.1.1 3,7]DECANE 3,4 DICARBOXY 3 HYDROXYBUTANOATE; PLACEBO; ABT-126; BUNGAROTOXIN RECEPTOR; NOOTROPIC AGENT; QUINUCLIDINE DERIVATIVE; THIADIAZOLE DERIVATIVE;

ADULT; ARTICLE; COGNITIVE DEFECT; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HUMAN; LEARNING; PRIORITY JOURNAL; RHINOPHARYNGITIS; SCHIZOPHRENIA; SCORING SYSTEM; SMOKING; TREATMENT DURATION; TREATMENT OUTCOME; WORKING MEMORY; ADVERSE EFFECTS; AGONISTS; ATTENTION; CLINICAL TRIAL; COGNITIVE DYSFUNCTION; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; MALE; MIDDLE AGED; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; PHASE 2 CLINICAL TRIAL; PSYCHOLOGY; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; SHORT TERM MEMORY; STATISTICS AND NUMERICAL DATA;

ADULT; ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ATTENTION; COGNITIVE DYSFUNCTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MEMORY, SHORT-TERM; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PSYCHOMETRICS; QUINUCLIDINES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SMOKING; THIADIAZOLES; TREATMENT OUTCOME; VERBAL LEARNING;

EID: 84991261565     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2015.15010093     Document Type: Article

References (30)

1. Keefe RS, Eesley CE, Poe MP: Defining a cognitive function decrement in schizophrenia. Biol Psychiatry 2005; 57:688-691
2. Green MF, Kern RS, Heaton RK: Longitudinal studies of cognition and functional outcome in schizophrenia: implications forMATRICS. Schizophr Res 2004; 72:41-51
3. Bowie CR, Harvey PD: Cognition in schizophrenia: impairments, determinants, and functional importance. Psychiatr Clin North Am 2005; 28:613-633
4. Bitner RS, Bunnelle WH, Anderson DJ, et al: Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. J Neurosci 2007; 27:10578-10587
5. CurzonP, AndersonDJ, Nikkel AL, et al: Antisenseknockdownof the rat alpha7 nicotinic acetylcholine receptor produces spatial memory impairment. Neurosci Lett 2006; 410:15-19
6. Mazurov A, Hauser T, Miller CH: Selective alpha7 nicotinic acetylcholine receptor ligands. Curr Med Chem 2006; 13:1567-1584
7. Dani JA, Bertrand D: Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol 2007; 47:699-729
8. Cohen AS, Forbes CB, Mann MC, et al: Specific cognitive deficits and differential domains of social functioning impairment in schizophrenia. Schizophr Res 2006; 81:227-238
9. BuchananRW, Davis M, Goff D, et al:Asummaryof theFDA-NIMHMATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull 2005; 31:5-19
10. Buchanan RW: Important steps in the development of cognitiveenhancing drugs in schizophrenia. Am J Psychiatry 2006; 163: 1867-1869
11. SheehanDV, Lecrubier Y, SheehanKH, et al:TheMini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59(suppl 20):22-33
12. Kern RS, Nuechterlein KH, Green MF, et al: The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry 2008; 165:214-220
13. Nuechterlein KH, Green MF, Kern RS, et al: The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry 2008; 165:203-213
14. Patterson TL, Goldman S, McKibbin CL, et al: UCSD Performance-Based Skills Assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr Bull 2001; 27: 235-245
15. Keefe RS, Fox KH, Harvey PD, et al: Characteristics of theMATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr Res 2011; 125:161-168
16. Alphs LD, Summerfelt A, Lann H, et al: The Negative Symptom Assessment: a new instrument to assess negative symptoms of schizophrenia. Psychopharmacol Bull 1989; 25:159-163
17. Axelrod BN, Goldman RS, Alphs LD: Validation of the 16-item Negative Symptom Assessment. J Psychiatr Res 1993; 27:253-258
18. Marder SR, Davis JM, Chouinard G:The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997; 58: 538-546
19. Barr RS, Culhane MA, Jubelt LE, et al: The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology 2008; 33:480-490
20. D'Souza MS, Markou A: Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophreniaassociated cognitive deficits. Neuropharmacology 2012; 62:1564-1573
21. Roncarati R, Scali C, Comery TA, et al: Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders. J Pharmacol Exp Ther 2009; 329:459-468
22. Olincy A, Harris JG, Johnson LL, et al: Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. ArchGenPsychiatry 2006; 63:630-638
23. Quick MW, Lester RA: Desensitization of neuronal nicotinic receptors. J Neurobiol 2002; 53:457-478
24. Martin LF, Kem WR, Freedman R: Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology (Berl) 2004; 174:54-64
25. Gentry CL, Lukas RJ: Regulation of nicotinic acetylcholine receptor numbers and function by chronic nicotine exposure. Curr Drug Targets CNS Neurol Disord 2002; 1:359-385
26. Smith RC, Singh A, Infante M, et al: Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology 2002; 27:479-497
27. Velligan D, Brenner R, Sicuro F, et al: Assessment of the effects of AZD3480 on cognitive function in patients with schizophrenia. Schizophr Res 2012; 134:59-64
28. Keefe RS, Meltzer HA, Dgetluck N, et al: Randomized, double-blind, placebo-controlled study of encenicline, an alpha7 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia. Neuropsychopharmacology 2015; 40:3053-3060
29. Freedman R, Olincy A, Buchanan RW, et al: Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 2008; 165: 1040-1047
30. Gault LM, Florian H, Ritchie C, et al: Efficacy and safety of the a7 agonist ABT-126 as a monotherapy treatment in mild-to-moderate Alzheimer's dementia: results of a phase 2b trial. AlzheimersDement 2014;10(suppl 4):137